Novartis' canakinumab reduces CV risk in CANTOS subgroup

Novartis AG (NYSE:NVS; SIX:NOVN) reported data from a subgroup of patients who achieved a high sensitivity C-reactive protein (hsCRP) level of <2 mg/L at three months after the first dose of subcutaneous canakinumab (ACZ885) in the Phase III CANTOS cardiovascular (CV) outcomes trial in patients with a

Read the full 476 word article

User Sign In